PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Positive results for Cerevance’s Parkinson’s drug

In phase 2 trials, the drug reduced ‘OFF time’ which refers to periods of the day when Parkinson’s symptoms recur despite medication

Cerevance has announced positive phase 2 trial results for the company’s first-in-class, once-a-day, orally-administered compound treating Parkinson’s disease.

The company is a private, clinical-stage drug discovery and development company focused on central nervous system diseases.

Beyond meeting safety objectives, the drug – CVN424 – also achieved a significant and meaningful reduction of periods in which Parkinson’s symptoms recur despite medication. These periods are referred to as ‘OFF time’. At a high dose, CVN424 demonstrated a 1.3-hour improvement in OFF time compared to the placebo at four weeks.

“We are delighted to report these results which we believe demonstrate that CVN424 can provide a significant improvement for patients, with little exacerbation of dopaminergic side effects,” said Brad Margus, Cerevance’s chief executive officer. “We look forward to rapidly advancing CVN424 into several larger clinical studies aimed at obtaining regulatory approval.”

The drug also had an encouraging side-effect profile, with adverse reactions of nausea, vomiting and headache only occurring in two subjects (4%), both at the higher dose.

Mark Carlton, chief scientific officer at Cerevance, added: “CVN424’s positive results demonstrate the power of the deep, cell-type-specific transcriptional and epigenetic data we are generating by applying our NETSseq platform technology to thousands of post-mortem human brain tissue samples. The data also increases the confidence we have in our pipeline of additional programmes against novel targets identified by our approach.”

CVN424 was evaluated in a randomised double-blind, placebo-controlled, multicentre phase 2 study, at two dose levels in Parkinson’s disease patients with motor fluctuations.

“For more than 50 years, physicians have relied on therapeutics that work by directly increasing dopaminergic signalling,” concluded Karl Kieburtz, president of Clintrex, which specialises in development pathways. “This new mechanism holds great promise for treating the motor fluctuations eventually experienced by all Parkinson’s disease patients, as well as the potential for treating patients in the earlier stages of the disease.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026